Biocon Q2 FY25 results: Net profit declines 84% to Rs 27.1 crore

Quick Summary:

With recent investments in the research and contract development and manufacturing organisation (CDMO) businesses, we are well-positioned to leverage opportunities for medium- to long-term growth,” highlighted Jonathan Hunt, CEO & managing director, Syngene International Limited.

This was Biocon Group’s debut bond issue, and its three-time oversubscription speaks to strong investor confidence in our biosimilars growth potential,” said Kiran Mazumdar-Shaw, chairperson, Biocon Group.

Reported operating revenues of Rs 3,590 crore reflect Y-o-Y growth of 8 per cent on a like-for-like basis, with core EBITDA and EBITDA margins at 28 per cent and 20 per cent respectively, remaining healthy.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Category: BusinessFinance

Markets: IndiaBrazilChinaOmanSingapore

Topics: Biocon Q2 results US Oncology and insulins franchises Biocon Q2 Pharma companies

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-10-30 @ 19:53:51 (1 days ago)

News Timezone: GMT +5:00

News Source URL: business-standard.com

Language: English

Article Length: 949 words

Reading Time: 6 minutes read

Sentences: 32 lines

Sentence Length: 30 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Business Standard

News ID: 23339619

View Article Analysis

About Business Standard

Main Topics: BusinessFinance

Official Website: business-standard.com

Update Frequency: 180 posts per day

Year Established: 1975

Headquarters: India

News Last Updated: 2 hours ago

Coverage Areas: India

Ownership: Independent Company

Publication Timezone: GMT +5:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #49

Publisher Details

Frequently Asked Questions